Neo-angiogenesis plays a key role in colorectal cancer, with the vascular endothelial growth
factor family proteins and their receptors in particular triggering multiple signaling networks …

VEGF/VEGFR signal axis has been proven to be an important target for development of
novel cancer therapies. One challenging aspect in small molecular VEGFR inhibitors is to …

Vascular endothelial growth factor C (VEGF-C) has been identified as a multifaceted factor
participating in the regulation of tumor angiogenesis and lymphangiogenesis. VEGF-C is not …

New blood vessel formation (angiogenesis) is fundamental to the process of tumor growth,
invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) …

Introduction The vascular endothelial growth factor A (VEGF) is the main mediator of
angiogenesis. In addition, VEGF contributes to cancer growth and metastasis directly …

New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

Vascularization is fundamental to the growth and spread of tumor cells to distant sites. As a
consequence, angiogenesis, the sprouting of new blood vessels from existing ones, is a …

Introduction: Ramucirumab (IMC-1121B) is a fully humanized IgG1 monoclonal antibody,
targeting the extracellular domain of VEGF receptor 2 (VEGFR2). Numerous Phase I–II trials …

It has been nearly 9years since the FDA (Food and Drug Administration) approved the first
anti-angiogenic drug (bevacizumab) for treatment of metastatic colorectal cancer. Other …

Angiogenesis, the formation of new blood vessels from preexisting ones, provides oxygen
and nutrients to actively proliferating tumor cells. Hence, it represents a critical aspect of …